Pfizer reports first-quarter results Tuesday before the open with a 10am EDT call, and Wall Street has set the bar at $13.82 billion of revenue and 74 cents of adjusted earnings per share — down from 92 cents in the year-earlier quarter. [1] The full-year guide is already on the page: $59.5 to $62.5 billion of revenue, $2.80 to $3.00 of adjusted EPS, adjusted gross margin in the mid-70s. [2] Tuesday's print is whether the quarter tracks the curve the company drew in February, or whether it slips below it.

The paper's Monday brief framed the print as the first major pharma report under a new post-pandemic baseline. The COVID-product franchise is guided to roughly $5 billion of revenue for the full year, $1.5 billion below 2025. [3] Paxlovid carries the heavier step-down. Comirnaty has flattened, the company has said, as patients absorbed narrowed government-eligibility rules.

The line the call has to defend is the operational growth metric — ex-COVID, ex-loss-of-exclusivity — guided at roughly 4 percent. [3] That figure is small enough that one weak segment can break it. Eliquis, Ibrance and Xeljanz all carry exclusivity declines running through 2028. The replacement candidates are the Seagen oncology assets and the obesity program acquired through Metsera, particularly the long-acting GLP-1 receptor agonist PF-3944. [4]

The most-tracked Q1 disclosure is VESPER-3, the Phase IIb readout for PF-3944. Chief Scientific Officer Chris Boshoff said in February that the data increased confidence in a Phase III monthly-dosing study expected later in 2026. [5] Whether Tuesday's call confirms a Phase III start date or signals a delay sets the obesity-segment narrative against the TrumpRx pricing pressure already dragging on Wegovy-pill and Eli Lilly's orforglipron, both ceiling-priced near $150 a month for initial doses. [6]

Pfizer trades at a forward dividend yield of 6.7 percent on a balance sheet still carrying Seagen acquisition debt. [7] The dividend's coverage ratio is the line investors will check first — before they read past the headline EPS number. A miss on operational growth at 4 percent puts coverage in the conversation. A clean print with a Phase III trigger date keeps the dividend conversation off the table for another quarter.

Cost-cutting is the other lever. Pfizer's restructuring program targeted $4.5 billion of net cost savings by year-end 2025 and another $1.5 billion in research-and-development reorganization through 2027. [8] The company's cost discipline carried fourth-quarter 2025 EPS above expectations even as revenue stepped down. The 74-cent consensus for Q1 already assumes that mechanic continues. The risk is that the input — operational-growth volume — does not.

The peer set is unhelpful. Eli Lilly's Mounjaro and Zepbound continue to grow against a price ceiling Pfizer has not had to defend yet. Novo Nordisk has cut guidance twice. Merck's Keytruda cliff arrives in 2028. The pharma-tape Pfizer prints into Tuesday is a tape that has rewarded the GLP-1 incumbents and discounted the rest. The valuation gap is what the obesity pipeline is priced to close.

The structural read is whether Pfizer prints a clean COVID floor at $5 billion plus an in-line operational-growth quarter — in which case the Phase III trigger is the next chapter — or whether the call admits a softer-than-guided operational quarter and the dividend yield re-rates wider. The headline EPS number tells one story; the call's commentary on PF-3944 and Eliquis volume tells the one that matters for the rest of 2026.

-- THEO KAPLAN, San Francisco